NeurAegis announced its scientific founder, Dr. Michel Baudry, has been awarded a multi-year, $3.8 million grant from the Department of Defense's Combat Casualty Care Research Program. This project is focused on optimizing a neuroprotective drug candidate for traumatic brain injury (TBI) and concussion and the DOD funds will support medicinal chemistry and preclinical studies in preparation for a first-in-human Phase I clinical trial.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"We have identified a molecular mechanism closely associated with cell death and damage following TBI and discovered a novel protease inhibitor that shows efficacy against this neurodegenerative process. Results from our in vivo animal model studies of TBI and repeated concussions are very encouraging," Dr. Baudry, Co-Founder of NeurAegis and principal investigator for this project, said.
NeurAegis is partnering with Western University of Health Sciences in Pomona, CA, and the laboratory of Dr. Baudry, a neuroscientist and expert in mechanisms of synaptic plasticity and neurodegeneration. NeurAegis has an exclusive worldwide license to commercialize technology from the Baudry Laboratory.